Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study
- PMID: 32730752
- PMCID: PMC8219057
- DOI: 10.1016/S2213-2600(20)30317-9
Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study
Erratum in
-
Correction to Lancet Respir Med 2020; 8: 873-84.Lancet Respir Med. 2021 Mar;9(3):e29. doi: 10.1016/S2213-2600(21)00088-6. Epub 2021 Feb 8. Lancet Respir Med. 2021. PMID: 33571467 No abstract available.
Abstract
Background: In pulmonary hypertension subgroups, elevated pulmonary vascular resistance (PVR) of 3·0 Wood units or more is associated with poor prognosis. However, the spectrum of PVR risk in pulmonary hypertension is not known. To address this area of uncertainty, we aimed to analyse the relationship between PVR and adverse clinical outcomes in pulmonary hypertension.
Methods: We did a retrospective cohort study of all patients undergoing right heart catheterisation (RHC) in the US Veterans Affairs health-care system (Oct 1, 2007-Sep 30, 2016). Patients were included in the analyses if data from a complete RHC and at least 1 year of follow-up were available. Both inpatients and outpatients were included, but individuals with missing mean pulmonary artery pressure (mPAP), pulmonary artery wedge pressure, or cardiac output were excluded. The primary outcome measure was time to all-cause mortality assessed by the Veteran Affairs vital status file. Cox proportional hazards models were used to assess the association between PVR and outcomes, and the mortality hazard ratio was validated in a RHC cohort from Vanderbilt University Medical Center (Sept 24, 1998-June 1, 2016).
Findings: The primary cohort (N=40 082; 38 751 [96·7%] male; median age 66·5 years [IQR 61·1-73·5]; median follow-up 1153 days [IQR 570-1971]), included patients with a history of heart failure (23 201 [57·9%]) and chronic obstructive pulmonary disease (13 348 [33·3%]). We focused on patients at risk for pulmonary hypertension based on a mPAP of at least 19 mm Hg (32 725 [81·6%] of 40 082). When modelled as a continuous variable, the all-cause mortality hazard for PVR was increased at around 2·2 Wood units compared with PVR of 1·0 Wood unit. Among patients with a mPAP of at least 19 mm Hg and pulmonary artery wedge pressure of 15 mm Hg or less, the adjusted hazard ratio (HR) for mortality was 1·71 (95% CI 1·59-1·84; p<0·0001) and for heart failure hospitalisation was 1·27 (1·13-1·43; p=0·0001), when comparing PVR of 2·2 Wood units or more to less than 2·2 Wood units. The validation cohort (N=3699, 1860 [50·3%] male, median age 60·4 years [49·5-69·2]; median follow-up 1752 days [IQR 1281-2999]) included 2870 patients [77·6%] with mPAP of at least 19 mm Hg (1418 [49·4%] male). The adjusted mortality HR for patients in the mPAP of 19 mm Hg or more group and with PVR of 2·2 Wood units or more and pulmonary artery wedge pressure of 15 mm or less Hg (1221 [42·5%] of 2870) was 1·81 (95% CI 1·33-2·47; p=0·0002).
Interpretation: These data widen the continuum of clinical risk for mortality and heart failure in patients referred for RHC with elevated pulmonary artery pressure to include PVR of around 2.2 Wood units and higher. Testing the generalisability of these findings in at-risk populations with fewer cardiopulmonary comorbidities is warranted.
Funding: None.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Figures
![Figure 1.](https://webcf.waybackmachine.org/web/20220826144141im_/https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8219057/bin/nihms-1700854-f0001.gif)
![Figure 2.](https://webcf.waybackmachine.org/web/20220826144141im_/https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8219057/bin/nihms-1700854-f0002.gif)
![Figure 2.](https://webcf.waybackmachine.org/web/20220826144141im_/https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8219057/bin/nihms-1700854-f0002.gif)
![Figure 3.](https://webcf.waybackmachine.org/web/20220826144141im_/https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8219057/bin/nihms-1700854-f0004.gif)
![Figure 3.](https://webcf.waybackmachine.org/web/20220826144141im_/https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8219057/bin/nihms-1700854-f0004.gif)
Comment in
-
Pulmonary hypertension thresholds: time to lower further?Lancet Respir Med. 2020 Sep;8(9):834-836. doi: 10.1016/S2213-2600(20)30326-X. Epub 2020 Jul 27. Lancet Respir Med. 2020. PMID: 32730751 No abstract available.
-
Assessment of Pulmonary Vascular Disease: Pulmonary Vascular Resistance, Exercise Hemodynamics, and Ventriculovascular Coupling.Am J Respir Crit Care Med. 2022 Jun 1;205(11):1349. doi: 10.1164/rccm.202107-1611RR. Am J Respir Crit Care Med. 2022. PMID: 35333146 No abstract available.
Similar articles
-
Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.Circulation. 2016 Mar 29;133(13):1240-8. doi: 10.1161/CIRCULATIONAHA.115.020207. Epub 2016 Feb 12. Circulation. 2016. PMID: 26873944 Free PMC article.
-
Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension.JAMA Cardiol. 2017 Dec 1;2(12):1361-1368. doi: 10.1001/jamacardio.2017.3882. JAMA Cardiol. 2017. PMID: 29071338 Free PMC article.
-
Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry.JACC Cardiovasc Imaging. 2013 Oct;6(10):1036-1047. doi: 10.1016/j.jcmg.2013.01.013. Epub 2013 Jun 13. JACC Cardiovasc Imaging. 2013. PMID: 23769494
-
Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension.Thorax. 2009 Oct;64(10):883-8. doi: 10.1136/thx.2008.112847. Epub 2009 Jun 21. Thorax. 2009. PMID: 19546096
-
Suicidal Ideation.2022 May 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. 2022 May 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 33351435 Free Books & Documents.
Cited by
-
The Paradox of Pulmonary Vascular Resistance: Restoration of Pulmonary Capillary Recruitment as a Sine Qua Non for True Therapeutic Success in Pulmonary Arterial Hypertension.J Clin Med. 2022 Aug 5;11(15):4568. doi: 10.3390/jcm11154568. J Clin Med. 2022. PMID: 35956182 Free PMC article.
-
Noninvasive diagnosis of pulmonary hypertension with hyperpolarised 129Xe magnetic resonance imaging and spectroscopy.ERJ Open Res. 2022 May 16;8(2):00035-2022. doi: 10.1183/23120541.00035-2022. eCollection 2022 Apr. ERJ Open Res. 2022. PMID: 35586448 Free PMC article.
-
Pulsatile pulmonary artery pressure in a large animal model of chronic thromboembolic pulmonary hypertension: Similarities and differences with human data.Pulm Circ. 2022 Jan 12;12(1):e12017. doi: 10.1002/pul2.12017. eCollection 2022 Jan. Pulm Circ. 2022. PMID: 35506099 Free PMC article.
-
Tadalafil for veterans with chronic obstructive pulmonary disease-pulmonary hypertension: A multicenter, placebo-controlled randomized trial.Pulm Circ. 2022 Mar 14;12(1):e12043. doi: 10.1002/pul2.12043. eCollection 2022 Jan. Pulm Circ. 2022. PMID: 35506072 Free PMC article.
-
Tetramethylpyrazine Improves Monocrotaline-Induced Pulmonary Hypertension through the ROS/iNOS/PKG-1 Axis.J Healthc Eng. 2022 Mar 24;2022:1890892. doi: 10.1155/2022/1890892. eCollection 2022. J Healthc Eng. 2022. PMID: 35368928 Free PMC article.
Publication types
MeSH terms
Grant support
- UL1 TR000445/TR/NCATS NIH HHS/United States
- T32 HL007633/HL/NHLBI NIH HHS/United States
- KL2 TR002542/TR/NCATS NIH HHS/United States
- I01 CX001892/CX/CSRD VA/United States
- K08 HL151976/HL/NHLBI NIH HHS/United States
- R21 HL145420/HL/NHLBI NIH HHS/United States
- R01 HL153502/HL/NHLBI NIH HHS/United States
- R01 HL128661/HL/NHLBI NIH HHS/United States
- R01 HL146588/HL/NHLBI NIH HHS/United States
- R01 HL139613/HL/NHLBI NIH HHS/United States
- U01 HL125215/HL/NHLBI NIH HHS/United States
- UL1 RR024975/RR/NCRR NIH HHS/United States
- R01 HL148727/HL/NHLBI NIH HHS/United States
- S10 RR025141/RR/NCRR NIH HHS/United States
- UL1 TR002243/TR/NCATS NIH HHS/United States
- R56 HL131787/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials